Rozlytrek Drug Interactions

Effect of Other Drugs on ROZLYTREK: Moderate and Strong CYP3A Inhibitors: Adults and Pediatric Patients 12 Years and Older with BSA Greater than 1.50 m²: Coadministration of ROZLYTREK with a strong or moderate CYP3A inhibitor increases entrectinib plasma concentrations [see Pharmacology: Pharmacokinetics under Actions], which could increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with ROZLYTREK. If coadministration is unavoidable, reduce the ROZLYTREK dose [see Pharmacology: Pharmacokinetics under Actions and Dosage Modifications for Drug Interactions under Dosage & Administration].
Pediatric Patients 12 Years and Older with BSA Less Than or Equal to 1.50 m²: Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors [see Pharmacology: Pharmacokinetics under Actions].
Avoid grapefruit products during treatment with ROZLYTREK, as they contain inhibitors of CYP3A.
Moderate and Strong CYP3A Inducers: Coadministration of ROZLYTREK with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations [see Pharmacology: Pharmacokinetics under Actions], which may reduce ROZLYTREK efficacy. Avoid coadministration of strong and moderate CYP3A inducers with ROZLYTREK.
Drugs That Prolong QT Interval: QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration of ROZLYTREK with other products with a known potential to prolong QT/QTc interval [see QT Interval Prolongation under Precautions and Pharmacology: Pharmacodynamics under Actions].